Role of B-lymphocyte activating factor (BAFF) in the pathogenesis of systemic lupus erythematosus
Tóm tắt
B-lymphocyte activating factor (BAFF) is a new member of the tumor necrosis factor family that promotes B-cell survival, acting as an antiapoptotic factor and thus contributing to the development of autoimmune disease. The aim of the study was to investigate the role of BAFF in the pathogenesis of systemic lupus erythematosus (SLE) by correlating its serum levels to different clinicopathological indices of disease activity. This is a prospective study that was conducted on 20 female patients with SLE. Ten healthy controls of matching age and sex were also included in this study. All patients were subjected to full history taking and clinical examination upon presentation, and the following laboratory parameters were evaluated: complete blood picture, erythrocyte sedimentation rate, serum (creatinine, blood urea nitrogen), and complete urine analysis (anti nuclear antibody, anti-dsDNA, C3, C4 in serum). Serum BAFF levels were measured by enzyme-linked immunosorbent assay in all patients. Renal biopsy was performed whenever necessary. Serum BAFF levels were significantly higher in patients with active SLE than in controls (P<0.05). These levels also correlated positively with systemic lupus erythematosus disease activity index (SLEDAI) in a highly significant manner (P<0.001). Correlating serum BAFF among patients with photosensitivity and symptoms of central nervous system affection proved to be highly significant (P<0.001). In addition, within this study, serum BAFF levels correlated positively with ESR levels among patients and negatively with both C3 and C4 in a significant manner (P<0.05 and 0.001, respectively). Serum BAFF levels were significantly higher among patients with active SLE than among controls. It correlated in a negative manner with both C3 and C4 – significantly with C3 and highly significantly with C4. BAFF levels also correlated with SLEDAI in a highly significant manner, implicating B-cell immunoglobulin production and immune complex formation in the disease activity of lupus patients.
Tài liệu tham khảo
Pisetsky DS. Systemic lupus erythematosis. I: Klippel JM, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic disease. 13th ed. Atlanta, Georgia: Arthritis foundation; 2008. pp. 319–326.
Anolik JH. B-cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007; 65:182–186.
Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570–576.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995–999.
Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med 1999; 189:1747–1756.
Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002; 23:113–115.
Castro J, Balada E, Ordi Ros J, Vilardell Tarrés M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 2008; 7:345–351.
Liu Y, Hong X, Kappler J, Jiang L, Zhang R, Xu L, et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 2003; 423: 49–56.
Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B-lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475–3486.
Carter R, Zhao H, Liu X, Pelletier M, ChathamW, Kimberly R. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52:3943–3954.
Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, et al. Expression of B-cell activating factor of the tumor necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology 2007; 46:1083–1086.
Petri M, Stohl W, Chatham W, McCune J, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453–2459.
Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39:1131–1137.
Badr ELdin A, Sayed S, Hegazy G, Shaker O. B-cell activating factor (BAFF) in systemic lupus erythematosus, rheumatoid arthritis, and Behc¸et’s disease and Behc¸et’s disease. Turkish J Rheumatol 2012; 27:185–194.
Zhang J, Roschke V, Baker K, Wang Z, Alarcon G, Fessler B. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166:6–10.
Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, et al. Regulatory mechanims for the production of BAFF and IL-6 are impaired in monocytes of patients with primary Sjögren’s syndrome. Arthritis Res Ther 2011; 13:R170.
Mariette X. How does BAFF activate B cells in patients with autoimmune diseases? Arthritis Res Ther 2012; 14:106.
Collins C, Gavin A, Migone T, Hilbert D, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8:R6.
Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to inl uence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778–785.